Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric maribavir study for CMV infection after transplant
jRCT2031230753Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, open-label trial of maribavir in cytomegalovirus disease (CMV) (3 cohorts), sponsored by Takeda. Primary endpoints: Maximum observed plasma concentration (Cmax) of maribavir, Time to maximum observed concentration (Tmax) of maribavir and 7 more. Started Nov 2023; status: recruiting.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on jRCT2031230753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230753.